News
IMMVF
3.000
NaN%
--
Immunovia Builds Case for PancreaSure in Hereditary High-Risk Pancreatic Cancer Market
TipRanks · 3d ago
Immunovia Launches SEK 63 Million Rights Issue to Fund PancreaSure Push
TipRanks · 09/28 17:10
Immunovia Calls Extraordinary Meeting to Enable Flexible Rights Issue
TipRanks · 09/28 17:09
Immunovia Seeks Medicare Coverage for PancreaSure Pancreatic Cancer Test
TipRanks · 09/28 12:32
Immunovia’s PancreaSure Registry Targets Real-World Impact in Early Pancreatic Cancer Detection
TipRanks · 09/04 16:31
Immunovia Survey Shows Strong Demand for Blood-Based Pancreatic Cancer Tests
TipRanks · 08/13 05:35
Immunovia AB Earnings Call: Early Traction, Funding Risks
TipRanks · 08/08 00:25
Immunovia boosts PancreaSure uptake as clinical evidence builds and cash burn stays below guidance
TipRanks · 08/06 07:05
Immunovia to Present Q2 2026 Report Amid Push in Pancreatic Cancer Diagnostics
TipRanks · 08/03 06:44
Immunovia Unveils New PancreaSure Data Ahead of Medicare Coverage Bid
TipRanks · 06/15 06:03
Immunovia’s PancreaSure Test Posts Strong Late-Stage Pancreatic Cancer Data in AFFIRM Study
TipRanks · 06/10 13:36
Immunovia AGM Backs New Share Issue Mandate and Major Option Program
TipRanks · 05/13 11:16
Immunovia Cuts Cash Burn as PancreaSure Expansion Nears Full U.S. Coverage
TipRanks · 05/07 07:33
Immunovia Cuts Cash Burn as PancreaSure U.S. Rollout Nears Nationwide Reach
TipRanks · 05/07 07:14
Immunovia Launches ASSURE Registry to Drive Real-World Adoption of PancreaSure
TipRanks · 05/05 06:55
Immunovia to Present Q1 2026 Results and Outline Strategic Objectives
TipRanks · 05/04 05:32
Immunovia Publishes 2025 Annual Report Focused on Pancreatic Cancer Diagnostics
TipRanks · 04/10 07:13
Immunovia Earnings Call: PancreaSure Builds, Risks Remain
TipRanks · 02/26 00:21
Immunovia Cuts Losses and Raises Capital as PancreaSure Gains U.S. Traction
TipRanks · 02/24 08:26
Immunovia Sets Webcast for Q4 2025 Results in Pancreatic Cancer Push
TipRanks · 02/23 18:02
More
Webull provides a variety of real-time IMMVF stock news. You can receive the latest news about Immunovia Ab through multiple platforms. This information may help you make smarter investment decisions.
About IMMVF
Immunovia AB (publ) is a Sweden-based diagnostic company that is developing and commercializing blood tests for the early detection of cancer and autoimmune diseases based on Immunovia’s test platform called IMMray. Tests are based on antibody biomarker microarray analysis using machine-learning and bioinformatics to single-out a set of relevant biomarkers that indicate a certain disease. Thus, forming a disease biomarker signature. Immunovia Dx Laboratories locations in USA and Sweden provides laboratory testing services in two accredited reference laboratories.